GISMO THERAPEUTICS INC.

Howard Beach, NY · Biotech · Private

Small molecule drug (GTC-3295) that inhibits amyloid-beta and tau protein interactions with heparan sulfate glycosaminoglycans to reduce neurodegeneration in Alzheimer's disease

Grants
$7.9M
11 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Glycosaminoglycan-Cytokine Inhibitors for Arthritis Therapy$224,997
Federal grantDepartment of Health and Human Services · Phase I · Glycosaminoglycan-Cytokine Inhibitors for Arthritis Therapy$224,997
Federal grantDepartment of Health and Human Services · Phase I · Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson's Therapeutic$241,938
Federal grantDepartment of Health and Human Services · Phase I · Glycosaminoglycan Interacting Small Molecule GISMO as Parkinson s Therapeutic$384,126
Federal grantDepartment of Health and Human Services · Phase I · Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson's Therapeutic$142,188
Federal grantDepartment of Health and Human Services · Phase II · Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics$933,415
Federal grantDepartment of Health and Human Services · Phase II · Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics$952,480
Federal grantDepartment of Health and Human Services · Phase II · Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease$983,932
Federal grantDepartment of Health and Human Services · Phase II · Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease$1,776,789
Federal grantDepartment of Health and Human Services · Phase II · Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease$792,857
Federal grantDepartment of Health and Human Services · Phase II · Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease$1,192,768
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1707Remedy Labs, Inc.—$500K
1708STOECKER MD, WILLIAM V——
1709MTI BIOTECH, INC.——
1710GISMO THERAPEUTICS INC.——
1711SINOPIA BIOSCIENCES INC——
1712NEUROGT INC——
1713Lila Sciences——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereofapplication
  • Compounds And Pharmaceutical Compositions Comprising Inhibitors Of Amyloid Peptide Interactions With Glycosaminoglycans, Methods Of Treatment, And Use Thereofapplication
  • Compounds And Pharmaceutical Compositions Comprising Inhibitors Of Amyloid Peptide Interactions With Glycosaminoglycans, Methods Of Treatment, And Use Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.